Skipping Prostate Screenings Raises Cancer Death Risk by 45%

Recent research highlights a concerning finding: men who skip prostate cancer screenings may increase their risk of dying from the disease by a staggering 45%. According to data from the Mayo Clinic, prostate cancer ranks among the most prevalent cancers globally, often diagnosed at an early stage and typically growing slowly. Early detection remains crucial, as many individuals can be successfully treated if the cancer is caught in its initial phases.

The study, which analyzed data from the European Randomized Study of Screening for Prostate Cancer (ERSPC), involved over 72,460 men from seven countries over two decades. It revealed that roughly one in six men, totaling more than 12,400, did not attend any screening appointments. Alarmingly, these non-attenders exhibited a 45% higher risk of death from prostate cancer compared to those who attended all recommended screenings.

Longitudinal data from the ERSPC consistently demonstrated that participation in screening programs is linked to a significant reduction in mortality risk. Men who received regular invitations and attended screenings had a 23% lower chance of dying from prostate cancer, while those who opted out faced a 39% increased risk.

Understanding Screening Attendance and Health Behaviour

The analysis was led by René Leenen, MD, a PhD researcher at the Erasmus MC Cancer Institute, part of the University Medical Center Rotterdam. Leenen emphasized the need to explore the reasons behind men’s decisions to skip screenings. She noted that these individuals might be “care avoiders,” less likely to engage in healthy behaviours and preventative health measures.

Leenen stated, “Our study identifies that men who were invited for screening but do not attend appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted the invitation.” This finding underscores the necessity of understanding the demographics and motivations of men who decline to participate in screenings, aiming to enhance engagement in future prostate cancer screening programs.

The implications of these findings are significant, particularly for European countries working to improve attendance in population-based screening initiatives.

Reevaluating Screening Benefits

The analysis also challenges previous assumptions about the benefits of prostate cancer screenings. Dr. Tobias Nordström, a Clinical Urologist at the Karolinska Institute in Sweden, remarked, “For countries around Europe that are planning to introduce a national prostate screening program, this analysis focusing on attendance shows that men who participate in screening have a much-improved long-term benefit than what we’ve seen from previous studies.”

Nordström called attention to the subgroup of men who are at greater risk of developing advanced prostate cancer due to their non-attendance. “We need to better understand why these men might actively choose not to participate in screening, despite being invited to attend,” he added.

Prostate cancer currently stands as the most common cancer among men in 112 countries, with projections indicating that cases could double by 2040. Implementing national screening programs that measure levels of prostate-specific antigen (PSA) in the blood could facilitate earlier treatment access and improve cure rates, potentially reducing the financial burden associated with advanced cancer care.

As research continues, understanding the patterns of screening attendance and its direct impact on prostate cancer outcomes remains a priority for healthcare professionals. The focus now shifts to developing strategies that encourage informed participation in screening programs, ultimately aiming to save lives.